Your browser doesn't support javascript.
loading
Reversibility of Bicalutamide PSMA PET-Positive Gynecomastia With Androgen Deprivation Therapy.
Muniz, Miguel; Childs, Daniel S; Orme, Jacob J; Johnson, Geoffrey B; Sartor, Oliver.
Afiliação
  • Muniz M; From the Division of Medical Oncology.
  • Childs DS; From the Division of Medical Oncology.
  • Orme JJ; From the Division of Medical Oncology.
  • Johnson GB; Division of Nuclear Medicine, Department of Radiology and Department of Immunology, Mayo Clinic, Rochester, MN.
  • Sartor O; From the Division of Medical Oncology.
Clin Nucl Med ; 49(4): e164-e165, 2024 Apr 01.
Article em En | MEDLINE | ID: mdl-38377363
ABSTRACT
ABSTRACT A 78-year-old man receiving bicalutamide for prostate cancer was referred for a PSMA PET/CT scan to evaluate his gradually rising prostate-specific antigen level. The PSMA PET/CT revealed gynecomastia with radiotracer uptake in bilateral breast parenchyma, a known but rarely reported effect of bicalutamide monotherapy. This scan also demonstrated metastatic progression of his disease in bone and lymph nodes, and he was started on leuprolide injections. Three months after a decrease in his testosterone level, the radiotracer uptake in his breast tissue had resolved, demonstrating that PSMA-avid bicalutamide-induced gynecomastia is reversible.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Compostos de Tosil / Ginecomastia / Anilidas / Nitrilas Limite: Aged / Humans / Male Idioma: En Revista: Clin Nucl Med Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Compostos de Tosil / Ginecomastia / Anilidas / Nitrilas Limite: Aged / Humans / Male Idioma: En Revista: Clin Nucl Med Ano de publicação: 2024 Tipo de documento: Article